- Home
- PTMN vs AARD Comparison
PTMN vs AARD Comparison
Compare PTMN & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTMN
- AARD
- Stock Information
- Founded
- PTMN 2006
- AARD 2017
- Country
- PTMN United States
- AARD United States
- Employees
- PTMN N/A
- AARD N/A
- Industry
- PTMN Finance: Consumer Services
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- PTMN Finance
- AARD Health Care
- Exchange
- PTMN Nasdaq
- AARD Nasdaq
- Market Cap
- PTMN 165.9M
- AARD 154.9M
- IPO Year
- PTMN N/A
- AARD 2025
- Fundamental
- Price
- PTMN $12.60
- AARD $14.70
- Analyst Decision
- PTMN Hold
- AARD Strong Buy
- Analyst Count
- PTMN 1
- AARD 5
- Target Price
- PTMN $14.00
- AARD $33.00
- AVG Volume (30 Days)
- PTMN 40.2K
- AARD 76.9K
- Earning Date
- PTMN 08-07-2025
- AARD 08-14-2025
- Dividend Yield
- PTMN 15.48%
- AARD N/A
- EPS Growth
- PTMN N/A
- AARD N/A
- EPS
- PTMN N/A
- AARD N/A
- Revenue
- PTMN $58,024,000.00
- AARD N/A
- Revenue This Year
- PTMN N/A
- AARD N/A
- Revenue Next Year
- PTMN $12.17
- AARD N/A
- P/E Ratio
- PTMN N/A
- AARD N/A
- Revenue Growth
- PTMN N/A
- AARD N/A
- 52 Week Low
- PTMN $11.48
- AARD $4.88
- 52 Week High
- PTMN $19.95
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- PTMN 52.95
- AARD N/A
- Support Level
- PTMN $12.45
- AARD N/A
- Resistance Level
- PTMN $12.73
- AARD N/A
- Average True Range (ATR)
- PTMN 0.22
- AARD 0.00
- MACD
- PTMN -0.03
- AARD 0.00
- Stochastic Oscillator
- PTMN 30.61
- AARD 0.00
About PTMN Portman Ridge Finance Corporation
Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.